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Abstract
Background: Lung volume reduction surgery is effective at improving lung function, quality of life,
and mortality in carefully selected individuals with advanced emphysema. Recently, less invasive
bronchoscopic approaches have been designed to utilize these principles while avoiding the
associated perioperative risks. The Endobronchial Valve for Emphysema PalliatioN Trial (VENT)
posits that occlusion of a single pulmonary lobe through bronchoscopically placed Zephyr®
endobronchial valves will effect significant improvements in lung function and exercise tolerance
with an acceptable risk profile in advanced emphysema.
Methods: The trial design posted on Clinical trials.gov, on August 10, 2005 proposed an
enrollment of 270 subjects. Inclusion criteria included: diagnosis of emphysema with forced
expiratory volume in one second (FEV1) < 45% of predicted, hyperinflation (total lung capacity
measured by body plethysmography > 100%; residual volume > 150% predicted), and
heterogeneous emphysema defined using a quantitative chest computed tomography algorithm.
Following standardized pulmonary rehabilitation, patients were randomized 2:1 to receive
unilateral lobar placement of endobronchial valves plus optimal medical management or optimal
medical management alone. The co-primary endpoint was the mean percent change in FEV1 and six
minute walk distance at 180 days. Secondary end-points included mean percent change in St.
George's Respiratory Questionnaire score and the mean absolute changes in the maximal work
load measured by cycle ergometry, dyspnea (mMRC) score, and total oxygen use per day. Per
patient response rates in clinically significant improvement/maintenance of FEV1 and six minute
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BMC Pulmonary Medicine 2007, 7:10 http://www.biomedcentral.com/1471-2466/7/10walk distance and technical success rates of valve placement were recorded. Apriori response
predictors based on quantitative CT and lung physiology were defined.
Conclusion: If endobronchial valves improve FEV1 and health status with an acceptable safety
profile in advanced emphysema, they would offer a novel intervention for this progressive and
debilitating disease.
Trial Registration: ClinicalTrials.gov: NCT00129584
Background
In this paper we describe the design of the Endobronchial
Valve for Emphysema Palliation Trial (VENT). The pri-
mary objective of this study is to evaluate patients with
heterogeneous emphysema treated with optimal medical
management including pulmonary rehabilitation with or
without implantation of the Emphasys (Emphasys Medi-
cal, Inc., Redwood City, CA) Endobronchial Valve (EBV).
Emphysema affects approximately 1.8% of the global
population[1]. The disease is characterized by the gradual,
irreversible breakdown of tissue and loss of elastic recoil
within the lungs, leading to a reduction in expiratory air-
flow. As this disease progresses, the diseased, hyper-
inflated regions of the lung continue to expand, imposing
on the effective volume for more viable lung tissue to
expand. As a result of these abnormalities in lung mechan-
ics producing static and dynamic hyperinflation, patients
exhibit a progressive increase in dyspnea, and reductions
in exercise tolerance and quality of life.
Standard medical treatments for emphysema, which
include smoking cessation, bronchodilators, pulmonary
rehabilitation programs, and long-term home oxygen
therapy, are aimed at providing improved exercise capac-
ity and quality of life.
Surgical treatments for emphysema include single or dou-
ble lung transplantation, lung volume reduction surgery
(LVRS), and bulla resection. Transplantation is greatly
limited by the small number of available donor organs
and may not prolong survival. Lung volume reduction
surgery, where the most diseased and hyper-inflated lung
tissue is surgically resected, has been shown to offer relief
to some subsets of patients with advanced emphysema
when other treatment options have failed [2-6]. The
National Emphysema Treatment Trial (NETT)[7] rand-
omized 1,218 patients with advanced emphysema to
either bilateral LVRS or standard medical therapy. In
NETT, patients with bilateral, predominantly upper-lobe
disease demonstrated sustained improvements in lung
function, exercise tolerance and quality of life as com-
pared to medical therapy alone. Moreover in the subgroup
with upper lobe disease and low exercise performance
post rehabilitation, a greater than 50% reduction in two
year mortality following LVRS was demonstrated. Bulla
resection is reserved for symptomatic emphysema
patients presenting with a giant bulla which occupies
more than 50% of the volume of a hemithorax.
The paradoxical effect of improving lung function by
removing substantial amounts of diseased lung tissue sug-
gests that breathlessness due to emphysema is a function
of mechanical inefficiencies imposed by marked eleva-
tions in end-expiratory lung volume. Researchers have
speculated that less invasive bronchoscopic approaches
can utilize these principles of isolating and deflating the
diseased, hyper-inflated regions to improve lung function
and symptoms while avoiding the risks associated with
LVRS.
Rationale for VENT
The Zephyr® Endobronchial Valve (EBV) (Emphasys Med-
ical, Inc., Redwood City, CA) is a bronchial implant incor-
porating a one-way valve that blocks the bronchial lumina
leading to a targeted region of emphysematous lung (see
Figure 1). The valve is supported by a stent-like self-
expanding retainer that secures the EBV in place. In order
to provide a complete seal during inspiration, the retainer
is encased in a silicone membrane. The one-way valve
allows gas to vent from the isolated lung segment during
exhalation while preventing air from refilling the isolated
lung area during inhalation (see Figure 2). The one-way
valve is also designed to allow mucus to be expelled in
order to reduce the likelihood of post-obstructive infec-
tion and to be removable if clinically indicated.
Non-controlled pilot studies using similar or earlier gen-
eration devices have been reported, showing improve-
ment in lung function in short term follow-up evaluations
(1–3 months after EBV implantation)[8]. Reported com-
plication rates were favorable with respect to LVRS
although pneumothorax incidence was 6.1% at 90 days.
VENT is the first prospective, randomized, multi-center
trial to study endobronchial valves. The primary objective
of VENT is to assess the safety and efficacy of EBV implan-
tation combined with pulmonary rehabilitation, com-
pared to optimal medical management with pulmonary
rehabilitation, in patients with heterogeneous emphy-Page 2 of 12
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patient characteristics or other procedural covariates that
may affect the outcome of EBV placement and to shed fur-
ther light on EBV mechanisms of improvement.
Methods
Overview
VENT is a two-arm, randomized, controlled, multi-center
trial designed to study the safety and efficacy of the EBV
implantation procedure, and the ability of the EBV to pro-
duce sustained improvement of symptoms in emphy-
sema. The study sample size was a minimum of 270
subjects with heterogeneous emphysema, with randomi-
zation at a ratio of 2 to 1 (i.e., two patients were rand-
omized to the study device treatment arm for every one
randomized to the control group).
Given the similarity in intended treatment effect between
LVRS and EBV implantation, combined with a goal of
allowing easy comparisons between the results of the
NETT and VENT, the VENT design largely followed that of
the NETT. The inclusion/exclusion criteria were similar
and both studies required pulmonary rehabilitation prior
to randomization in order to maximize function prior to
intervention. Both studies allowed treatment of the upper
or lower lobes based on CT analysis; however, the NETT
required bilateral (left and right lung) treatment whereas
VENT treatments were unilateral only. Patient randomiza-
tion in VENT was stratified per the subgroups identified in
the NETT according to lung treatment region (upper ver-
sus lower) and post rehabilitation pre-treatment exercise
capacity (low versus high).
In addition, the VENT study design conformed to the con-
sensus recommendations of an independent panel of
physician specialists convened by the U.S. Food and Drug
Administration in February of 2003 to provide study
design input for emerging bronchoscopic treatments for
emphysema[10]. Questions considered at the panel
included appropriate control groups, safety assessment,
appropriate outcome metrics, and length of follow up.
A double-blinded sham controlled study design was con-
sidered for VENT, but was determined to be unsuitable for
a number of reasons. Since the implants are radiopaque,
it would be difficult to maintain the blind. Post-procedure
chest x-rays are mandated by the protocol and are often
clinically indicated along with CT scans during the man-
agement of the patient during the follow up period. For
example, COPD exacerbations, a frequent occurrence in
patients of this severity, are often seen with radiographs in
the local emergency room. Maintaining the blind from
emergency room physicians and radiologists would be
problematic. Bronchoscopy during the follow up period
would also un-mask the treatment arm. A patient may
Implanted Zephyr® Endobronchial Valve end viewFigure 2
Implanted Zephyr® Endobronchial Valve end view. 
The Zephyr® Endobronchial Valve vents during expiration 
(left) and seals during inspiration (right) immediately after 
placement.
Zephyr® Endobronchial Valve side viewFigure 1
Zephyr® Endobronchial Valve side view.Page 3 of 12
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blind. Additionally, treatment decisions may differ based
on the presence of an implant, forcing primary caregivers
to unblind study subjects for evaluation and management
of adverse events. Even if sham bronchoscopies were per-
formed, patient recall of bronchoscopy procedures during
moderate sedation is present in many cases. A sham pro-
cedure becomes less important as more objective effort-
independent lung function parameters are included in the
comparative analysis (e.g., residual volume measure-
ments). Lastly, performing an unnecessary sham broncho-
scopic implant in control patients with no chance of
benefit, given their fragile health status, was considered to
carry unacceptable risk.
A Clinical Events Committee (CEC) consisting of two pul-
monologists and two thoracic surgeons adjudicates all
reported complications. The CEC characterizes the sever-
ity of each reported event (mild, moderate, severe) and
determines whether the event is related to the endobron-
chial valve or procedure (not related, remote possibility,
possible, probable, unknown). Adjudicated complica-
tions are summarized and presented to an independent
Data and Safety Monitoring Board (DSMB) consisting of
two pulmonologists, two thoracic surgeons, and a biostat-
istician. The DSMB establishes pre-defined safety stopping
rules and meets regularly to determine whether the study
safety profile warrants continuation of the study.
Primary outcome measures
The co-primary effectiveness endpoints are the mean per-
cent change in both forced expiratory volume in one sec-
ond (FEV1) and distance traveled in the six minute walk
test (6 MWT) in the treatment group (EBV implantation)
as compared to the control group (optimal medical man-
agement) at 180 days after randomization. The primary
safety endpoint is a comparison of major complications
between the two groups over the initial follow-up period
of 180 days. Additionally, patients will be followed for up
to 3 years post randomization for long term safety assess-
ment.
Secondary outcome measures
Disease specific quality of life (as measured by St. George's
Respiratory Questionnaire), exercise capacity as measured
by incremental cycle ergometry, daily supplemental oxy-
gen requirement, and dyspnea (as measured by the mod-
ified Medical Research Council (mMRC) dyspnea scale,
(see Table 1) are secondary efficacy endpoints to be
assessed at baseline and 180 days post randomization.
Appropriate adjustments will be made to account for
impact on Type I error[11].
Patient recruitment
Study sites were encouraged to advertise for local recruit-
ment, and web-links to study information were provided
to relevant organizations (e.g.: the American Lung Associ-
ation and the National Emphysema Foundation). Addi-
tionally, enrolling physicians were given written study
information and a slide presentation for referring physi-
cians in their area.
Patient consent
Patients identified as potential participants were provided
detailed explanations of the study and were asked for
informed consent prior to initial screening. The patient
consent form was approved by the Institutional Review
Board (IRB) of all study sites, and failure to provide
informed consent rendered the patient ineligible for the
study.
Screening assessments and high resolution computed 
tomography (HRCT)
Consented patients began an initial medical screening to
assess preliminary eligibility including demographic data,
medical history, physical exam, and inclusion/exclusion
criteria screening. The procedures for assessment and
determination of patient eligibility are outlined in Table 2
Table 1: Outcome measures
Co-primary efficacy endpoints Mean % change in FEV1 and 6 MWT in the treatment group as compared to control group at 180 days post 
randomization.
Primary safety endpoint Major Complications Composite at 180 days post randomization.
Secondary efficacy endpoints Mean absolute change in:
- St. George's Respiratory Questionnaire
- Maximal work load as measured by cycle ergometry
- Daily oxygen requirement
- mMRC
Secondary safety endpoints Complications (type, timing, and severity, including Kaplan-Meier survival analysis)
Device-related adverse events during procedure hospitalization
Device-related adverse events post discharge
Abbreviations: FEV1 = forced expiratory volume in one second, 6 MWT = six minute walk test, RV = residual volume, DLco = diffusion of the lung 
for carbon dioxide, BODE index = body-mass index, airflow obstruction, dyspnea, and exercise capacity index, EBV = endobronchial valve, mMRC 
= modified Medical Research Council dyspnea scalePage 4 of 12
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try, plethysmography, diffusing capacity, exercise toler-
ance, and a high resolution computed tomography
(HRCT) scan of the chest.
The standardized volume acquisition CT was performed
under the auspices of the imaging core at the David Geffen
School of Medicine at UCLA. All images were acquired on
multi-detector scanner platforms whose acquisition
parameters were standardized to ensure similar image
noise characteristics. Two sequences were acquired supine
at suspended TLC and at RV, each in a single breathhold.
The two sequences were reconstructed in both thick (5 or
10 mm) and thin (1.25 to 3 mm) series. Other sample
acquisition parameters were customized for each site
based on the scanner being utilized (e.g.: for the Siemens
Sensation 16 scanner, the settings would be 120 kVp, 80
effective mAs, 0.5 sec. rotation time, 16 × 0.75 mm colli-
mation, and 18 mm/rotation table feed with pitch 1.5).
The inclusion criteria identified patients with severe heter-
ogeneous emphysema who have not previously under-
gone LVRS or EBV implantation and who were able to
complete all the assessment and follow-up procedures.
Candidates for this study were required to meet all of the
inclusion criteria described in Table 3. The exclusion crite-
ria were designed to identify potential study subjects that
were unlikely to benefit from the treatment due to pre-
existing conditions, or were unable to complete all of the
follow-up assessments. Candidates were excluded from
the study if any of the conditions listed in Table 4 were
present.
In the NETT, all HRCT data was analyzed visually by study
site radiologists, and the lung was analyzed by zones that
represented 33% of each lung. Visual grading of lung
destruction due to emphysema has been shown to be
highly dependent on the radiologist performing the anal-
ysis, and to be much less consistent than quantitative
computer analysis[12]. The NETT study has subsequently
applied computer based analysis to the HRCT scan data,
although using the same lung zone convention that was
establish for the radiologist reads. For this reason, auto-
mated computer analysis of the thick section CT scan data
taken prior to randomization was used in VENT to deter-
mine patient eligibility for the study as well as to deter-
mine implant targeting for those patients in the treatment
arm. The core radiology laboratory established CT scan
acquisition quality standards to ensure that all scans,
regardless of study site location, were taken under repeat-
able and consistent conditions. In addition, the core lab
subdivided the lung into lobes and provided emphysema
scoring on a lobar basis. Unlike the NETT study which
used a zonal scoring system that did not correspond to
lobar anatomy, the lobar scoring in VENT allowed target-
ing of the EBV implantation procedure to the most
emphysematous lobe.
The baseline CT scan was provided to the CT core lab for
analysis using a modification of the system used in the
NETT study, a system adapted from prior work by God-
dard et al[13], Bergin et al[14], and Bankier at al[12]. In
the system used in VENT (see Table 5), the extent of
emphysematous destruction was graded on a lobar level
on a scale of 0 to 4 and called the emphysema score (ES).
Because the intent of EBV treatment in the VENT trial was
to completely isolate a targeted lobe, each lobe was graded
individually according to the percentage area that demon-
strated changes suggestive of emphysema, specifically,
low attenuation, lung destruction, and vascular disrup-
tion. Using a predefined formula (see figure 3), the lobe
targeted for isolation with EBV devices was determined by
the core lab radiologists for each patient based on the CT
scan analysis. The core lab radiologists were blinded to
any clinical or physiological information on the patients.
VENT study treatments
Medical treatment and pulmonary rehabilitation
After preliminary determination of eligibility, all subjects
received an optimal medical management program. Opti-
Table 2: Screening and eligibility procedures
1. Patient referred to study physician
2. Patient consent obtained
3. Screening Assessment 1: medical history, supplemental oxygen use and physical exam
4. Determine if patient meets eligibility criteria
5. Screening Assessment 2: electrocardiogram, spirometry, plethysmography, DLco, 6 MWT, Computed Tomography Scan, PaO2, PaCO2, 
arterial saturation, continine level, alpha-1 antitrypsin concentration
6. Determine if patient continues to meet eligibility criteria
7. Patient enters and completes pulmonary rehabilitation program
8. Baseline measurements taken: medications, supplemental oxygen use, physical exam, electrocardiogram, spirometry, plethysmography, DLco, 
6 MWT, cycle ergometry, quality of life surveys, chest x-ray, ventilation/perfusion (V/Q) scan, PaO2, PaCO2, arterial saturation, blood 
electrolytes, liver profile, renal profile, CBC, pregnancy test (where appropriate), and continine level
9. Final determination of patient eligibility
10. Randomization to Control or Treatment arm of the VENT study.
Abbreviations: DLco = diffusion of the lung for carbon monoxide, 6 MWT = six minute walk test, PaO2 = arterial pressure of oxygen, PaCO2 = 
arterial pressure of carbon dioxide, CBC = complete blood count.Page 5 of 12
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protocol, as maximal medical treatment for stable chronic
obstructive pulmonary disease (COPD) as presented in
the 2001 National Institutes of Health/World Health
Organization Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guidelines[15]. As recommended
in the GOLD standards, each patient enrolled in the study
received therapy consisting of the following components:
education and smoking cessation support, pharmacologi-
cal treatments including bronchodilators and influenza
and pneumococcal vaccinations, non-pharmacological
treatment including a 6–8 week pulmonary rehabilitation
program and oxygen therapy if needed.
Pulmonary rehabilitation was an essential component of
the pre-randomization optimal medical management
program. Pulmonary rehabilitation has been shown to
significantly improve exercise capacity and quality of life
in COPD[16]. A pulmonary rehabilitation program was
required for both control and treatment patients in the
NETT study, and thus its inclusion in VENT allows more
accurate comparisons between the results of both trials.
Pulmonary rehabilitation prior to randomization was
required in VENT to insure that any outcome differences
between the treatment and control groups were due to the
effect of the device rather than due to a training effect. It
also minimized the chance for differences in health care
Table 4: VENT exclusion criteria
HRCT scan An HRCT Emphysema Score of 4-4-4 in the right lung or 4-4 in the left lung.
Evidence of large bullae (encompassing >30% of either lung) in a non-target lobe.
Pulmonary 
function
FEV1 < 15% predicted value.
DLco < 20% predicted value.
Clinically significant bronchiectasis.
Pulmonary nodule requiring surgery.
History of recurrent respiratory infections (>1 hospitalization in the last year).
Clinically significant (> 4 tablespoons per day) sputum production.
Cardiovascular 
and exercise
Dysrhythmia that might pose a risk during exercise or training.
Congestive heart failure within 6 mo and LVEF < 45%.
Resting bradycardia (< 50 beats/min), frequent multifocal PVCs, complex ventricular arrhythmia, or sustained SVT.
Myocardial infarction within 6 mo and LVEF < 45%.
Clinical suspicion or proven history of pulmonary hypertension.
History of exercise-related syncope.
Patient is unable to complete 3 minutes of unloaded peddling on cycle ergometer.
Surgical Prior lung transplant, lung volume reduction surgery, median sternotomy, bullectomy or lobectomy.
General medical Unplanned weight loss of >10% usual weight in 90 days prior to enrollment or total body weight < 70% of ideal body weight.
Alpha-1 antitrypsin deficiency.
Fever, elevated white cell count, or other evidence of active infection.
Evidence of systemic disease or neoplasia expected to compromise survival during 5-yr period.
Any disease or condition that interferes with completion of initial or follow-up assessments.
Patient is currently enrolled in another clinical trial or has been previously enrolled in the VENT Trial for which protocol 
required follow up is not complete.
Abbreviations: HRCT = high resolution chest computed tomography, FEV1 = forced expiratory volume in one second, DLco = diffusion of the lung 
for carbon monoxide, LVEF = left ventricular ejection fraction, PVC = premature ventricular contractions, SVT = supraventricular tachycardia.
Table 3: VENT inclusion criteria
History and physical Age from 40 to 75 years.
BMI ≤ 31.1 kg/m2 (men) or ≤ 32.3 kg/m2 (women).
Stable with < 20 mg prednisone (or equivalent) daily.
The patient has no child bearing potential OR a negative pregnancy test in a woman of childbearing potential.
HRCT scan Patient diagnosed by HRCT Core Lab with eligible heterogeneous emphysema.
Pulmonary function FEV1 < 45% of predicted value.
TLC > 100% predicted.
RV > 150% predicted.
Blood gas PaCO2 < 50 mm Hg (Denver < 55 mm Hg).
PaO2 > 45 mm Hg (Denver > 30 mm Hg) on room air.
Exercise Post rehabilitation 6-minute walk of ≥ 140 meters.
Smoking Nonsmoking for 4 months prior to initial interview and throughout screening.
Plasma continine level < 13.7 ng/ml (or arterial carboxyhemoglobin < 2.5% if using nicotine products).
Consent Patient has provided written informed consent using a form that has been reviewed and approved by the IRB/EC.
Rehabilitation and follow-up The patient is willing and able to complete protocol required baseline assessments and procedures.
The patient agrees to all protocol required follow-up intervals.
Abbreviations: BMI = body-mass index, HRCT = high resolution chest computed tomography, FEV1 = forced expiratory volume in one second, TLC 
= total lung capacity, RV = residual volume, PaO2 = arterial pressure of oxygen, PaCO2 = arterial pressure of carbon dioxide, IRB = institutional 
review board, EC = Ethics Committee.Page 6 of 12
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assigned treatment groups. Upon successful completion
of the pulmonary rehabilitation program, a full baseline
assessment was performed in each patient as outlined in
table 2. If the patient continued to meet all protocol entry
criteria shown in Tables 3 and 4, the patient was rand-
omized to either the treatment or control group.
Control group
Once patients were randomized, the control group con-
tinued to receive optimal medical care at the participating
center. Exercise continued at a minimum frequency of
three times weekly. The control patients received the same
follow-up as the treatment arm, including an office visit in
lieu of EBV implantation. At the time of the control arm
office visit, all patients were provided with a study diary to
be used as a memory aid throughout the study duration.
Treatment group
The study group received the EBV implantation procedure
within three weeks of randomization, and continued opti-
mal medical management and exercise similar to the con-
trol group.
The goal of the implantation procedure was to completely
isolate a single diseased lobe of the lungs by implanting
EBV devices occluding all bronchial lumina leading to the
targeted lobe. Bilateral treatment was not allowed in this
study and acceptable target lobes did not include the right
middle lobe. A single segmental airway not isolated by
valves may allow ventilation to the lobe, thus reducing the
potential benefit of the EBV devices. EBV devices were
placed at the lobar, segmental, or sub segmental levels in
this order of preference, depending on the anatomy of the
patient noted at the time of the procedure.
The EBV implantation procedure was performed with the
patient under general anesthesia and on a ventilator, or
under moderate sedation with unassisted breathing. All
patients were given antibiotics before and for 7 days fol-
lowing the procedure. Anesthesia was administered
according to standard local protocols for bronchoscopy.
For general anesthetic procedures, a rigid bronchoscope in
conjunction with a flexible bronchoscope or a flexible
bronchoscope alone through an endotracheal tube was
allowed for valve placement.
Patients in both control and treatment arms were moni-
tored for 1 year, with scheduled assessments at 1, 2–3, 7–
10, 30, 90, 180, and 365 days post-procedure. Follow-up
assessment includes the same variables as in the baseline
assessment (see Table 2) with the primary outcome meas-
ures defined from the 180 ± 14 day follow-up visit.
Analysis
The power analysis is based on a pilot study in 38 patients
in which FEV1 improved 14.9% ± 33.7 (mean ± SD) and 6
MWT distance improved 20.4% ± 41.5%. The samples
size required to detect a 15% improvement in the treat-
ment arm in FEV1 and a 17% improvement in 6 MWT dis-
tance at an alpha of 0.05 and a power of 0.90 is a
minimum of 270 subjects with a 2:1 randomization to
EBV procedure. Both of these values are above the thresh-
old for minimal clinically important differences for these
tests[17-19].
Lobar treatment targeting algorithmFigu e 3
Lobar treatment targeting algorithm. A single lobe for 
treatment is selected by determining the highest emphysema 
score (ES). If emphysema scores are identical between lobes 
on both lungs, then the lung with the most heterogeneity is 
selected. The heterogeneity score (HS) is derived by sub-
tracting the best lobe score from the worst lobe score in a 
single lung. If both lungs are equally affected with emphysema 
and heterogeneity, the computer generated absolute % den-
sity score (DS) is used to select the most affected lobe for 
targeting.








Target Lung with 
greatest heterogeneity 
based on quantitative 
% emphysema score
Target RUL or 
RLL, whichever 




DS = Density Score
ES = Emphysema Score






has upper or 
lower ES ≥ 3?
Target LUL or 
LLL, whichever 
has the higher 
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Target LUL or 
LLL, whichever 
has the higher 
ES
Target RUL or 
RLL, whichever 
has the higher 
ES
Target LUL or 
LLL, whichever 
has the higher 
ES
Target RUL or 
RLL, whichever 
has the higher 
ES
Table 5: Lobar emphysema scoring
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mary outcomes, the study is only considered a success if
both endpoints show an improvement (one-sided test at
p < 0.025). A one-sided test is appropriate to test for supe-
riority. The actual probability of a false positive is lower
than 0.025 given the imperfect correlation of the two end-
points. If change in FEV1 and change in 6 MWT were inde-
pendent, the probability of a false positive would be
0.025*0.025 = 0.000625. In the pilot study generating the
null hypothesis, the correlation coefficient between the
change in FEV1 and 6 MWT was 0.3889. Given this r, the
alpha for achieving a positive outcome is actually 0.005
(0.025*0.025^(1/(1+0.3889))). This is an assurance of
avoiding a false positive well beyond convention.
The 2:1 randomization is chosen to enhance enrollment
and increase the EBV population numbers in order to
study covariates of treatment response. Although the 2:1
randomization increases the number of subjects required
for the study, more robust subgroup comparisons may be
possible.
For safety the 95% upper confidence interval for the Major
Complication Composite rate delta between the EBV arm
and the control arm is ≤ 30%.
The primary analysis cohort is intent to treat. As such, all
180 day missing data will be imputed using either a
regression methodology if 30 and 90 day data are present
or hot-deck imputation if there are not multiple
datapoints available for a particular subject for regression
analysis. Three unbiased imputations will be performed
and the imputation resulting in the highest p-values will
be selected as the final intent to treat dataset.
The initial analysis will evaluate the mean percent change
between EBV and control in FEV1 and 6 MWT using an
unpaired t-test if data are normally distributed or Mann-
Whitney-Wilcoxon test if data require non-parametric
testing. To determine if covariates impact the primary out-
come variables, and to adjust for potential imbalances in
randomization, both primary endpoints will be further
tested via a multivariate model (SAS PROC MIXED). In
order to reduce the possibility of over-specification of the
model, the potential covariates listed in Tables 6, 7, 8, 9
will be subjected to a univariate screening procedure sim-
ilar to that described by Hosmer and Lemeshow[20]. Der-
ivations for these variables are provided in Table 10. Main
effects and interactions with a p-value of 0.15 or less are
allowed to enter a multivariate analysis using a mixed lin-
ear model (SAS PROC MIXED). The treatment effect must
remain in the model in order to substantiate the one-
Table 6: Plethysmography, spirometry and HRCT derived baseline potential covariates*
Variable Plethysmography/Spirometry HRCT at TLC HRCT at RV TLC and RV HRCT †
RV X
RV % Predicted X
TLC X




FVC % Predicted X
FEV1 X
FEV1 % Predicted X
FEV1/FVC X
Destruction Score of Target Lobe X X
Ipsilateral Heterogeneity†† X X
Whole Lung Heterogeneity†† X X
For RUL Treatment Subset only: RUL-RML Heterogeneity†† X X
Target Lobe Volume % of TLC X
Target Lobe Volume % of RV X
Max Destruction Score other than target X X
Min Destruction Score other than target X X
Target Lobe Destruction Score % TLC-RV Delta X
Target Lobe Volume % TLC-RV Delta X
Fissure Score††† X
*Variables marked in multiple columns will be calculated twice, once using the expiratory (RV) CT and once using the inspiratory (TLC) CT. All 
tests are at Baseline.
†Some variables require information from both the TLC and RV CT
†† Heterogeneity scores are derived by subtracting the minimum destruction score from the maximum destruction score.
††† Fissure Score is an integer scale from one to three base on visual scoring by core center radiologists (1 = Fissure Absent, 2 = Incomplete Fissure, 
3 = Complete Fissure).Page 8 of 12
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statistically significant interactions with the treatment arm
via the mixed model analysis will be further analyzed in
follow-on sub-group analyses. In order to limit the impact
of multiple hypothesis testing, univariate sub-set analysis
will be performed using only those independent variables
that remain in the mixed model as interactions with the
treatment arm. For those analyses performed on the
remaining independent variables, appropriate adjust-
ments will be made to account for impact on Type I
error[11]. Secondary endpoint analyses will follow the
same methodology as described above.
Thirty, 90, and 365 day results will also be collected and
reported. Post hoc analysis will use these datapoints to
define the speed of treatment success if present.
Discussion
Bronchoscopic lung volume reduction holds the promise
of improving outcomes for carefully selected individuals
with lung hyperinflation from heterogeneous emphy-
sema. Pilot studies have been performed in small num-
bers of patients that demonstrate improvements in FEV1
and exercise tolerance [4,21-24].
The current trial serves dual purposes. The first was to treat
enough of the hyper-inflated lung to achieve a statistically
significant improvement in physiology and symptoms.
While there is certainly limitation to the amount of lung
that can be safely treated without suffering hypoventila-
tion or respiratory failure, the optimal amount of lung
that can be safely targeted remains unknown. An analysis
of pilot studies has suggested that a single lobar treatment
strategy may be a reasonable goal for obtaining meaning-
ful physiologic improvements in some patients. However,
the outcome of this study is not expected to achieve the
same physiologic outcomes that might be obtained by
LVRS that targets 20–30% of both lungs during a single
operative procedure.
The second goal was to carefully evaluate the safety of the
EBV procedure and post procedural course. Pilot studies
have documented a high frequency of pneumothorax fol-
lowing the procedure. Whether this represents pleural dis-
ruption by valve placement, rupture of residual blebs
subsequent to stress relaxation in non-treated segments or
a delay in lung remodeling following significant atelecta-
sis of targeted lung remains unknown. Some clues to the
pathogenesis will be obtained by an observation strategy
imbedded in the protocol. Treatment of pneumothorax
with a thoracostomy tube will be reserved for pneumoth-
oraces that enlarge or cause respiratory failure.
COPD outcome is heavily influenced by exacerbation fre-
quency. Since EBV valves are foreign bodies in an airway
that may have some baseline hyper-responsiveness, the
frequency and severity of exacerbations and the frequency
of post-obstructive pneumonia are important safety con-
siderations that warrant a long follow-up time.
Advanced emphysema is characterized by destruction of
lung parenchyma and augmentation of anatomic connec-
tions for air passage between adjacent lung lobules.
Unfortunately for endobronchial lung volume reduction
procedures, these collateral communications may traverse
lobar fissures [25]. These peripheral communications
between lobes then may allow for continued lobar venti-













Upper vs. Lower X






*These potential covariates apply only to the treatment arm and do 
not have a control arm subset.
Table 9: 180 day follow-up CT potential covariate*
Variable 180 Day HRCT at TLC Baseline and 180 Day HRCT at TLC Baseline and 180 Day HRCT at RV
Target Lobe Atelectasis Score† X X
Lobar Exclusion†† (yes/no) X
*These potential covariates apply only to the treatment arm and do not have a control arm subset.
†Atelectasis Score is a continuous variable from 0 to 100% and is defined as the % volume change in the target lobe from baseline to 180 day follow-
up.
††Lobar Exclusion will be determined by the core lab radiologists and is defined as all airways into the target lobe are occluded by valves at day 180.Page 9 of 12
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Table 10: Covariate variable derivations
Variable Definition
RV Residual Volume by Spirometry and Plethysmography (TLC - Max (FVC or VC))
TLC Total Lung Capacity by Plethysmography
VC Vital Capacity by Plethysmography
FVC Forced Vital Capacity by Spirometry
FEV1 Forced Expiratory Volume in the First Second by Spirometry
Target Lobe RUL, RLL, LUL, or LLL
RUL RUL Target vs. Others
Density Score Density Score by Lobe
Total Density Score Sum of all Lobar Density Scores (including RML)
Ipsilateral DS Heterogeneity Target - Max DS of Non-treated Lobes within Treated Lung [e.g.: RUL - Max(RML, RLL)]
Thorax DS Heterogeneity Target DS - Max DS of All Non-treated Lobes [e.g.: RUL - MAX (RML, RLL, LUL, LLL)]
Target Lobe DS % Delta (TLC HRCT - RV HRCT)/TLC HRCT Density Score of Target Lobe
Target Lobe Volume % Delta (TLC HRCT Volume - RV HRCT)/TLC HRCT Volume of Target Lobe




NETT Strata 1 = Upper-Lobe Predominance, Low Baseline Exercise Capacity*
2 = Upper-Lobe Predominance, High Baseline Exercise Capacity
3 = Non-Upper-Lobe Predominance, Low Baseline Exercise Capacity
4 = Non-Upper-Lobe Predominance, High Baseline Exercise Capacity
Target Lobe Atelectasis Scores % change in Target Lobe Volume at TLC and at RV between Baseline and 180-day HRCT
Lobar Exclusion Yes, If all bronchial pathways to target lobe are sealed by valve(s) – adjudicated by HRCT Core Lab
Valve Combinations 1. Small ONLY
2. Small AND Large
3. Large Only
Large Valve Any procedure with Only Large Valves vs. all others
Small Valve Any procedure with Only Small Valves vs. all others
*Low Exercise Capacity by Cycle Ergometry ≤ 25 W for Women, ≤ 40 W for Men
Table 8: Composite or other potential covariate interactions
Composite or Interactions Definition
Baseline BODE BMI, FEV1% predicted, MMRC, 6 MWT Composite Score
NETT Strata Randomization Stratification by Baseline Cycle Ergometry and HRCT at TLC
NETT Strata by Right vs. Left Randomization Stratification by Baseline Cycle Ergometry and HRCT at TLC, by Right or Left Lung
Lobar Exclusion by Fissure Interaction* Fissure Score = 3 AND Lobar Exclusion = Yes vs. all others
Lobar Exclusion, Fissure, and RV % Predicted* Lobar Exclusion = Yes AND Fissure Score = 3 AND RV % Predicted ≥ 200% vs. all others
Lobar Exclusion, Fissure, and RV % Predicted* Lobar Exclusion = Yes AND Fissure Score = 3 AND RV % Predicted ≥ 200% vs. all others
Large Valve by Right vs. Left* Right vs. Left Lung AND Large Only vs. Others
Small Valve by Right vs. Left* Right vs. Left Lung AND Small Only vs. Others
Expectorated Valve Replaced* Valve(s) Expectorated AND Lobar Exclusion = Yes vs. all others
Expectorated Valve Not Replaced* Valve(s) Expectorated AND Lobar Exclusion = No vs. all others
Lobar Exclusion by Site* Technical Success by Site
First Case by Site* First Treatment Case by Site vs. All Others
Learning Curve by Site* Experience Level: Case 1, vs. 2 & 3, vs. 4–6, vs. 7–9, vs. ≥10 by site.
*These potential covariates apply only to the treatment arm and do not have a control arm subset.
BMC Pulmonary Medicine 2007, 7:10 http://www.biomedcentral.com/1471-2466/7/10lation despite completely occluded lobar airways. Because
this collateral ventilation is not easily quantified by cur-
rent detection methods, the outcome of EBV valve place-
ment may be heterogeneous. Ultimately, secondary
analyses will include responder analysis, in order to deter-
mine the proportion of patients with clinically meaning-
ful responses.
Given the complex mechanical and gas exchange conse-
quences of valve insertion, it is possible that the magni-
tude of volume reduction in a lobe may not be associated
with changes in other meaningful physiologic or func-
tional indices following the procedure. For example, the
impact of valve placement on symptoms associated with
dynamic hyperinflation or variations in gas exchange uti-
lizing collateral channels may be associated with clinical
improvements independent of changes in conventional
resting pulmonary tests. The composite primary endpoint
was chosen to include a functional exercise measure to
capture such changes.
Ultimately, the future of the EBV valve will be determined
by the balance between efficacy and safety. Since the
valves are removable for mild or moderate adverse events,
valve safety will be impacted by the frequency of severe
adverse events that might affect survival in a compro-
mised patient population. In fact, individuals who dem-
onstrate improvements in lung function may also
demonstrate an increase in exacerbation frequency. For
this reason, quality of life indices including the Quality of
Well Being Scale and the Saint George's Respiratory Ques-
tionnaire are considered integrative parameters which can
determine the balanced impact of the intervention
[26,27]. One strategy to minimize overall adverse
response would be to remove valves earlier in the patients
who do not have clinically important responses. If a
meaningful outcome is measurable in the first few days
after the procedure, future alternative targeting strategies
might be employed to determine response at earlier times
after randomization.
Study limitations
One limitation of this study is the difficulty in performing
a double-blind sham procedure study for reasons dis-
cussed earlier. As such, a potential placebo effect could
influence the quality of life and exercise measurements.
From the investigator's perspective the frequency of
adverse events attributable to the valve will obviously be
different for the control and valve cohorts. Common but
potentially serious adverse events such as exacerbation
frequency may be interpreted differently given the knowl-
edge of treatment assignment. Despite attempts to stand-
ardize insertion protocol, there remains considerable
variability related to delivery of general or moderate seda-
tion anesthesia that could affect procedure time and pos-
sibly outcome. Finally, the rigid inclusion criteria and
targeting algorithms utilized in this trial limit the discov-
ery of other potentially effective emphysema treatment
strategies. Given the many subtypes of emphysema, the
outcome of this study may not generalize to all individu-
als with the disease.
The VENT study evaluates the effectiveness of endobron-
chial valve placement to reduce lung volume in emphyse-
matous patients as compared to optimal medical
management. Due to the similarities between this study
and the NETT study of lung volume reduction surgery,
efficacy and safety comparisons to those achievable with
LVRS are anticipated.
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